Work

Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity

Year: 2013
Type: article
Abstract: Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications - seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.
Authors: Kishore Gadde, Shin
Institution: Duke Medical Center
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,836
OpenAlex ID: W2000866847
FWCI: 4.787
Cites: 61
Cited by: 236
Related to: 10